Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares were up 5% during mid-day trading on Friday . The company traded as high as $5.28 and last traded at $5.28. Approximately 4,397 shares changed hands during trading, a decline of 100% from the average daily volume of 2,264,275 shares. The stock had previously closed at $5.03.
A number of equities analysts have recently issued reports on LXRX shares. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 28th. Citigroup lifted their target price on Lexicon Pharmaceuticals from $13.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, August 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $10.29.
The firm has a market capitalization of $713.70 million, a P/E ratio of 12.67 and a beta of 1.46. The stock has a fifty day simple moving average of $4.08 and a two-hundred day simple moving average of $4.67.
Institutional investors have recently made changes to their positions in the business. Royal Bank of Canada grew its stake in Lexicon Pharmaceuticals by 283.8% in the first quarter. Royal Bank of Canada now owns 4,652 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 3,440 shares during the period. Amalgamated Bank acquired a new stake in Lexicon Pharmaceuticals in the second quarter valued at approximately $50,000. HighTower Advisors LLC acquired a new stake in Lexicon Pharmaceuticals in the first quarter valued at approximately $64,000. Credit Suisse AG acquired a new stake in Lexicon Pharmaceuticals in the first quarter valued at approximately $65,000. Finally, Citigroup Inc. grew its stake in Lexicon Pharmaceuticals by 234.1% in the second quarter. Citigroup Inc. now owns 11,595 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 8,124 shares during the period. 84.85% of the stock is owned by hedge funds and other institutional investors.
Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, a treatment for heart failure and type 1 diabetes.
See Also: What is a dead cat bounce?
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.